Combat Group
  • Home
  • Healthcare Professionals
    • Urology
      • Clinical Evidence
      • BRS HIVEC Systems
      • Training Resources
      • HIVEC Clinical Trials
    • Surgical Oncology
      • Clinical Evidence
      • PRS+ HIPEC System
      • Training Resources
      • HIPEC Clinical Trials
  • Products
    • BRS HIVEC (Bladder Cancer)
    • PRS HIPEC (Peritoneal Cancers)
  • Patient Support
    • Bladder Cancer Patients HIVEC
    • Bladder Cancer Patients HIVEC Deutsch
    • Surgical Oncology Patients HIPEC
  • Global Partners
    • BRS HIVEC Distributors
    • PRS HIPEC Distributors
  • About Us
    • Company
    • News Feed
    • Investors
    • Team
      • Advisory Board
      • Board and Senior Management Team
    • Contact
  • Our Blog
  • en EN
    • en EN
    • es ES
Select Page
“If patients aren’t fit for or don’t want to have a cystectomy, and prefer bladder preservation, HIVEC is a very good option for them”

“If patients aren’t fit for or don’t want to have a cystectomy, and prefer bladder preservation, HIVEC is a very good option for them”

by Combat Cancer | Mar 25, 2022 | The Medical Innovators Interview

The Medical Innovators Interview #3 Helena BurdenDecember 2021 Welcome to the third of our new series of interviews with medical innovators – in conversation with Miss Helena Burden, consultant urology surgeon at the Bristol Urological Institute, Southmead Hospital,...
“I think that in ten years we’ll have HIPEC in every single theatre, and with improvements like CO2 agitation it makes even more sense”

“I think that in ten years we’ll have HIPEC in every single theatre, and with improvements like CO2 agitation it makes even more sense”

by Combat Cancer | Mar 25, 2022 | The Medical Innovators Interview

The Medical Innovators Interview with Associate Professor Ahmad Sayasneh | November 2021 The regular use of HIPEC for ovarian cancer, along with improving pre-surgical diagnostics and visualisation interoperatively, could be a real game-changer. Consultant...
“There’s definitely more work to be done in the BCG-unresponsive field”

“There’s definitely more work to be done in the BCG-unresponsive field”

by Combat Cancer | Mar 25, 2022 | The Medical Innovators Interview

Welcome to Combat Medical’s first Medical Innovators interview series, where we’ll be exploring ideas and developments in the medical and clinical worlds with the people at the, ahem, cutting edge. To kick off, we’re talking haematuria, urine biomarkers and...
Next Entries »

Recent Posts

  • Could Vitamin D Play a Role in the Prevention and Treatment of Colorectal Cancer?
  • AI-Powered OncoRedox Colorectal Cancer Sensor
  • “SampleCam” – Could This Tiny Robotic Device Be An Alternative To Invasive Colonoscopies For High-Risk Patients?
  • Genetics and Bowel Cancer Risk
  • Combat’s Upcoming HIVEC®-HEAT Study 2025

Recent Comments

    Archives

    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • July 2023
    • January 2023
    • December 2022
    • August 2022
    • May 2022
    • April 2022
    • March 2022

    Categories

    • Hyperthermia
    • News
    • The Medical Innovators Interview
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Stay informed about the COMBAT Group
    For more information contact: Combat Medical Group
    UK (+44) 1582 343 120 | Spain (+34) 910 46 89 71
    Privacy statement